Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

12 treatments under study, led by Irinotecan

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Completed2
Recruiting1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07895498Phase 2Recruiting

A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

NCT00332163Phase 2Completed

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy

NCT01015326CompletedPrimary

Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT01380262Unknown

Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment

Showing all 4 trials

Research Network

Common Treatments

  • Irinotecan1
  • Minocycline1
  • Questionnaire1
  • Photoprotection1
  • Preemptive Skin Treatment1

Active Sponsors

  • Amgen1
  • Memorial Sloan Kettering Cancer Center1
  • Northwestern University1
  • Maria Sklodowska-Curie National Research Institute of Oncology1

Top Investigators

Related Conditions

  • Colorectal Cancer2
  • Skin Rash1
  • Colon Cancer1
  • Metastatic Colorectal Cancer1
  • Pancreatic Cancer1

Activity Timeline